Rheumatoid Arthritis and novel carrier systems in diagnosis and treatment: An AI generated review

Rheumatoid arthritis (RA) is a debilitating autoimmune disease that primarily affects the small joints of the hands and feet, leading to chronic inflammation, pain, and progressive joint damage. This inflammatory condition results from an overactive immune response, where CD4+ T cells, B cells, and macrophages infiltrate the synovium, triggering an aggressive immune attack on healthy tissues. Conventional treatments, including non-steroidal anti-inflammatory drugs, corticosteroids, and disease-modifying antirheumatic drugs, provide symptomatic relief but often come with significant side effects and limited long-term efficacy. Recent advancements in targeted therapy and nanomedicine have revolutionized RA treatment, offering innovative drug delivery systems designed to magnify therapeutic outcomes while lessen systemic toxicity. Emerging approaches, such as polypeptide nanogels, exosome-based therapy, silk fibroin hydrogels, and ROS-responsive polymeric micelles, hold great promise in improving drug bioavailability and precision targeting of inflamed joints. Moreover, novel strategies like macrophage repolarization, solute carrier nutrient transporters, and dendritic nanotheranostics are reshaping the landscape of RA therapeutics by modulating immune responses at a cellular level. This comprehensive review highlights the latest breakthroughs in RA treatment, emphasizing the potential of nanotechnology, biomaterials, and personalized medicine in addressing the limitations of traditional therapies. By integrating cutting-edge drug delivery mechanisms and immune-modulating strategies, these advancements open the way for a more effective, safer, and patient-centric approach to managing rheumatoid arthritis.